Evidence map›Paper›PMID 30385653›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression.

Vincent Bernard, Alexander Semaan, Jonathan Huang, F Anthony San Lucas, Feven C Mulu, Bret M Stephens, Paola A Guerrero, Yanqing Huang, Jun Zhao, Nabiollah Kamyabi and 9 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 257 papers.

0numbers the graph read from it
0cells of the map it votes in
257citing papers in PubMed
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

257 citing papers in PubMed, 400 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Tumor-Derived LAMB3 Drives Immunosuppressive LRRC15Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Catching pancreatic cancer early: Are we there yet?Journal of the National Cancer Center · 2026
    Review
  17. Tumorigenesis and Tumor Microenvironment in Lung Cancer.Current issues in molecular biology · 2026
    Review
  18. Article
  19. Article
  20. Article

197 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Vincent Bernard *Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Alexander Semaan *Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID https://orcid.org/0000-0001-5424-3217
Jonathan Huang *Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
F Anthony San Lucas *Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Feven C MuluDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Bret M StephensDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Paola A GuerreroDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yanqing HuangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jun ZhaoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Nabiollah KamyabiDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID https://orcid.org/0000-0002-3712-2066
Subrata SenDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Paul A ScheetDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cullen M TaniguchiDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID https://orcid.org/0000-0002-8052-3316
Michael P KimDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ching-Wei TzengDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Matthew H KatzDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Aatur D SinghiDepartment of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Anirban MaitraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hector A AlvarezDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. HAAlvarez@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USUniversity of Pittsburgh Medical Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
UPR/MDACC Partnership for Excellence in Cancer Research(Parent Grant U54 CA096297)U54CA096297 · NCI · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI Ilka C Rios · 2002 to 2026
$36.9M
UPR/MDACC Partnership for Excellence in Cancer Research (Luis Segarra supplement)U54CA096300 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Larkin Strong · 2002 to 2026
$23.8M
Project 3: Inhibiting Oxidative Phosphorylation in Pancreatic CancerP50CA221707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT, MAITRA, ANIRBAN · 2019 to 2023
$11.0M
Clinical Validation Center for Early Detection of Pancreatic CancerU01CA200468 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANIRBAN MAITRA · 2016 to 2026
$11.0M
Imaging and Molecular Correlates of Progression in Cystic Neoplasms of the PancreasU01CA196403 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MAITRA, ANIRBAN · 2015 to 2020
$5.8M
Center for Clinical and Translational Sciences (CCTS)KL2TR000370 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$4.3M
Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsiesR01CA218230 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT, MAITRA, ANIRBAN · 2018 to 2022
$3.3M
Translational Applications in an Animal Model of Pancreatic Cystic Neoplasm and CancerR01CA218004 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MAITRA, ANIRBAN · 2018 to 2021
$2.4M
NCATS NIH HHS KL2 TR000370NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA221707NCI NIH HHS R01 CA218004NCI NIH HHS R01 CA218230NCI NIH HHS U01 CA196403NCI NIH HHS U01 CA200468NCI NIH HHS U54 CA096297NCI NIH HHS U54 CA096300
6 · The paper itself

Abstract

purposeEarly detection of pancreatic ductal adenocarcinoma (PDAC) remains elusive. Precursor lesions of PDAC, specifically intraductal papillary mucinous neoplasms (IPMNs), represent a EXPERIMENTAL

designSingle-cell RNA sequencing was performed through droplet-based sequencing on 5,403 cells from 2 low-grade IPMNs (LGD-IPMNs), 2 high-grade IPMNs (HGD-IPMN), and 2 PDACs (all surgically resected).

resultsAnalysis of single-cell transcriptomes revealed heterogeneous alterations within the epithelium and the tumor microenvironment during the progression of noninvasive dysplasia to invasive cancer. Although HGD-IPMNs expressed many core signaling pathways described in PDAC, LGD-IPMNs harbored subsets of single cells with a transcriptomic profile that overlapped with invasive cancer. Notably, a proinflammatory immune component was readily seen in low-grade IPMNs, composed of cytotoxic T cells, activated T-helper cells, and dendritic cells, which was progressively depleted during neoplastic progression, accompanied by infiltration of myeloid-derived suppressor cells. Finally, stromal myofibroblast populations were heterogeneous and acquired a previously described tumor-promoting and immune-evading phenotype during invasive carcinogenesis.

conclusionsThis study demonstrates the ability to perform high-resolution profiling of the transcriptomic changes that occur during multistep progression of cystic PDAC precursors to cancer. Notably, single-cell analysis provides an unparalleled insight into both the epithelial and microenvironmental heterogeneities that accompany early cancer pathogenesis and might be a useful substrate to identify targets for cancer interception.

Indexed as

Adenocarcinoma, MucinousCarcinoma, Pancreatic DuctalDisease ProgressionHumansPancreatic NeoplasmsPhenotypeTumor Microenvironment

Identifiers

PMID30385653
PMCPMC6445737
OpenAlexW2798728508

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.